StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research report sent to investors on Tuesday. The brokerage issued a sell rating on the stock.
A number of other research firms have also commented on MBRX. Roth Mkm reaffirmed a buy rating and issued a $40.00 price objective on shares of Moleculin Biotech in a research note on Friday, April 12th. Maxim Group decreased their target price on Moleculin Biotech from $45.00 to $20.00 and set a buy rating for the company in a research report on Tuesday, March 26th.
Read Our Latest Stock Analysis on MBRX
Moleculin Biotech Trading Up 1.0 %
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Moleculin Biotech stock. Armistice Capital LLC bought a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 3,207,417 shares of the company’s stock, valued at approximately $2,753,000. Armistice Capital LLC owned 9.60% of Moleculin Biotech as of its most recent SEC filing. 15.52% of the stock is owned by hedge funds and other institutional investors.
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.
See Also
- Five stocks we like better than Moleculin Biotech
- Earnings Per Share Calculator: How to Calculate EPS
- Garmin Navigates to New Highs Driven By Wearables Trend
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Are Penny Stocks a Good Fit for Your Portfolio?
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.